Negotiation Policy Architectures
Cohort Drug Levers
0.18
Academic consensus estimates $0.15–$0.22 R&D curtailment per $1.00 net commercial revenue erosion.
Macro Fiscal & Patient Impact Ledger
Federal Medicare Savings
$9.63B
Patient OOP Relief
$2.14B
Net Biotech Revenue Shift
-$7.49B
R&D Reinvestment Delta
-$1.35B
Fiscal Balance Decomposition (D3 Waterfall)
Detailed Therapeutic Category Settlement
| Molecule & Class | Base Spend | Negotiated Disc. | Medicare MFP | Fed Savings | Patient Copay |
|---|